Cognition Therapeutics Inc. is a drug discovery and development company
info@cogrx.com

CogRx appears in BioPharma Dealmakers

Focusing on synaptic protection in Alzheimer’s

Cognition Therapeutics, Inc. has a first-in-class, clinical-stage, highly brain-penetrant and orally bioavailable small molecule designed to halt the initiation and progression of Alzheimer’s disease.

Link to the article